Health-related quality-of-life results from SANET-ep: A phase III study of surufatinib versus placebo for advanced extrapancreatic neuroendocrine tumors.

被引：0
|
作者：
Bai, Chunmei
Xu, Jianming
Shen, Lin
Li, Jie
Zhou, Zhiwei
Chi, Yihebali
Li, Zhiping
Xu, Nong
Li, Enxiao
Liu, Tianshu
Bai, Yuxian
Yuan, Ying
Li, Xingya
Wang, Xiuwen
Chen, Jia
Ying, Jieer
Li, Jing
Fan, Songhua
Peng, Mengye
Su, Weiguo
机构：
[1] Peking Union Med Coll Hosp, Beijing, Peoples R China
[2] Gen Hosp Peoples Liberat Army, Med Ctr 5, Dept Gastrointestinal Oncol, Beijing, Peoples R China
[3] Peking Univ Canc Hosp & Inst, Minist Educ, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Oncol, Beijing, Peoples R China
[4] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Peoples R China
[5] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr, Beijing, Peoples R China
[6] West China Hosp, Chengdu, Peoples R China
[7] Zhejiang Univ, Affiliated Hosp 1, Dept Med Oncol, Hangzhou, Peoples R China
[8] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Med Oncol, Xian, Peoples R China
[9] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[10] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[11] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China
[12] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Peoples R China
[13] Shandong Univ, Qilu Hosp, Dept Chemotherapy, Jinan, Peoples R China
[14] Jiangsu Canc Hosp, Nanjing, Peoples R China
[15] Univ Chinese Acad Sci, Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China
[16] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[17] Hutchis MediPharma Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4613
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies
    Li, J.
    Cheng, Y.
    Bai, C.
    Xu, J.
    Shen, L.
    Zhou, Z.
    Li, Z.
    Chi, Y.
    Yu, X.
    Li, E.
    Xu, N.
    Liu, T.
    Lou, W.
    Bai, Y.
    Yuan, X.
    Wang, X.
    Yuan, Y.
    Chen, J.
    Guan, S.
    Fan, S.
    Su, W.
    ESMO OPEN, 2022, 7 (02)
  • [22] Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial
    Cella, D.
    Pickard, A. S.
    Duh, M. S.
    Guerin, A.
    Mishagina, N.
    Antras, L.
    Neary, M. P.
    McCann, L.
    Hodge, R.
    Sternberg, C. N.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (03) : 311 - 323
  • [23] Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial.
    Strosberg, Jonathan R.
    Wolin, Edward M.
    Chasen, Beth
    Kulke, Matthew H.
    Bushnell, David L.
    Caplin, Martyn E.
    Baum, Richard P.
    Kunz, Pamela L.
    Hobday, Timothy J.
    Hendifar, Andrew Eugene
    Oberg, Kjell E.
    Sierra, Maribel Lopera
    Kwekkeboom, Dik J.
    Ruszniewski, Philippe B.
    Krenning, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [24] Health-related quality of life assessment in contemporary phase III trials in advanced colorectal cancer
    Adamowicz, Krzysztof
    Saad, Everardo D.
    Jassem, Jacek
    CANCER TREATMENT REVIEWS, 2016, 50 : 194 - 199
  • [25] Health-related quality of life (HRQoL) of patients with advanced gastrointestinal stromal tumors (GIST) treated with regorafenib (REG) vs placebo (P) in the phase III GRID trial
    Chang, J.
    Casali, P. G.
    Reichardt, P.
    Kang, Y. K.
    Blay, J. Y.
    Wu, Y.
    Odom, D.
    Kuss, I.
    Demetri, G. D.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S886 - S886
  • [26] Health-related quality of life (HRQoL) of patients with advanced gastrointestinal stromal tumors (GIST) treated with regorafenib (REG) vs placebo (P) in the phase III GRID trial
    Bauer, S.
    Chang, J.
    Casali, P. G.
    Reichardt, P.
    Kang, Y-K
    Blay, J-Y
    Wu, Y.
    Odom, D.
    Kuss, I.
    Demetri, G. D.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 58 - 58
  • [27] Effect of nivolumab on health-related quality of life in patients with treatment-na⟨ve advanced melanoma: results from the phase III CheckMate 066 study
    Long, G. V.
    Atkinson, V.
    Ascierto, P. A.
    Robert, C.
    Hassel, J. C.
    Rutkowski, P.
    Savage, K. J.
    Taylor, F.
    Coon, C.
    Gilloteau, I.
    Dastani, H. B.
    Waxman, I. M.
    Abernethy, A. P.
    ANNALS OF ONCOLOGY, 2016, 27 (10) : 1940 - 1946
  • [28] Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer
    Efficace, F
    Biganzoli, L
    Piccart, M
    Coens, C
    Van Steen, K
    Cufer, T
    Coleman, RE
    Calvert, HA
    Gamucci, T
    Twelves, C
    Fargeot, P
    Bottomley, A
    EUROPEAN JOURNAL OF CANCER, 2004, 40 (07) : 1021 - 1030
  • [29] Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer
    Cortes, J.
    Baselga, J.
    Im, Y. -H.
    Im, S. -A.
    Pivot, X.
    Ross, G.
    Clark, E.
    Knott, A.
    Swain, S. M.
    ANNALS OF ONCOLOGY, 2013, 24 (10) : 2630 - 2635
  • [30] Subgroup analysis by Ki-67 and baseline CgA of the randomized, placebo-controlled phase 3 study of surufatinib in advanced well-differentiated pancreatic neuroendocrine tumors (SANET-p).
    Yu, Xianjun
    Xu, Jianming
    Shen, Lin
    Bai, Chunmei
    Li, Jie
    Zhou, Zhiwei
    Li, Zhiping
    Li, Enxiao
    Yuan, Xianglin
    Chi, Yihebali
    Yin, Yongmei
    Lou, Wenhui
    Xu, Nong
    Bai, Yuxian
    Zhang, Tao
    Xiu, Dianrong
    Wang, Xiuwen
    Guan, Sha
    Xu, Qian
    Su, Weiguo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345